“ARG’s acquisition of CCA represents a natural next step and an exciting growth opportunity," said Lyle Camblos, President and cofounder of ARG.
CHARLOTTESVILLE, Va. and LONDON (PRWEB) December 04, 2018
Atlantic Research Group (ARG), an established North American full-service contract research organization (CRO), announced the acquisition of CCA Clinical Research (CCA), a leading European CRO. Effective immediately, the transaction significantly strengthens ARG’s reach and experience in the management of clinical trials.
Founded in 2004, ARG is an industry leader in rare disease, immunology, and oncology clinical trials management. CCA, founded in 1988 and recognized for its network of clinical research experts across Europe, has been an ARG strategic partner since 2007. The combination of the two companies creates a comprehensive, global, clinical trial management solution for small to mid-sized biotech companies.
As a result of the acquisition, ARG will expand its workforce to approximately 100 employees as executives identify talent to serve a larger and more diverse client base in Boston, Philadelphia, San Francisco and Raleigh, and globally in Western Europe, the Middle East, and Asia.
“CCA has always been the right fit; we are very pleased to report that this is the right time. Our confidence in this transaction moving forward is based on knowing we now have an experienced, global team to provide a full suite of best-in-class development services to the Biotech and Pharma industry in all phases of development,” said Paul Bishop, ARG’s CEO and cofounder, adding that the acquisition is part of a process that will lead to future transactions in other countries and on other continents.
Dr. Ignazio Di Giovanna, founder and CEO of CCA, will become Vice-President of European Operations for ARG. “We are delighted to transition to our new home at ARG. Both companies have earned the reputation of providing patient-centric, flexible, and engaged approaches to our partners. Moving forward, the unique combination of joint resources allows us to serve more clients in more markets,” Di Giovanna said.
“ARG’s acquisition of CCA represents a natural next step and an exciting growth opportunity. Our long-standing relationship with CCA is based on many commonalities, from serving similar clients to using similar technologies and processes to sharing company values. This is a marriage of two world-class teams with a common vision,” Lyle Camblos, President and cofounder of ARG, said.
ARG is a rare disease, oncology and immunology-focused contract research organization that provides comprehensive clinical program development services ranging from pre-launch consulting to commercialization. Founded in 2004, ARG has experienced consistent growth across the globe, expanding our reach to include drug and device trial management in diverse and wide-ranging therapeutic areas. ARG has remained true to our original vision: every project is highly significant and visible, delivered through strategic collaboration with partners. ARG is rare for a reason: we successfully operationalize development projects because we believe everyone deserves to be well.
CCA specializes in the management of proof of concept, early, and late-phase clinical trials, from protocol development to final report. Founded in 1988, CCA has built considerable expertise in rare diseases, oncology, and immunology, as well as in neurodegenerative and neuromuscular disorders, neonatal conditions, and issues affecting the metabolic or endocrine systems. CCA also possesses expertise in managing all aspects of medical device studies. CCA delivers trials without tribulations, earning a reputation for delivering high-quality services on time and on budget.